isosilybin

flavanolignan from Silybum marianum

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Biedermann, David: 1 article (03/2016)
2.	Rajnochová Svobodová, Alena: 1 article (03/2016)
3.	Ulrichová, Jitka: 1 article (03/2016)
4.	Vostálová, Jitka: 1 article (03/2016)
5.	Zálešák, Bohumil: 1 article (03/2016)
6.	Beijnen, Jos H: 1 article (08/2013)
7.	Maas-Bakker, Roel F: 1 article (08/2013)
8.	Meijerman, Irma: 1 article (08/2013)
9.	Mooiman, Kim D: 1 article (08/2013)
10.	Moret, Ed E: 1 article (08/2013)

1.	Phototoxic Dermatitis (Phototoxicity) 03/01/2016 - "The primary purpose of this study was to examine the phototoxicity of silymarin and its flavonolignans, silybin, isosilybin, silychristin, silydianin and 2,3-dehydrosilybin by validated 3T3 NRU assay. " 03/01/2016 - "The results showed that silymarin and the flavonolignans silybin, isosilybin, silychristin and silydianin had no phototoxicity towards any of the cells used. "
2.	Prostatic Neoplasms (Prostate Cancer) 04/01/2010 - "The isolation and structure elucidation of these two new compounds, which we have termed isosilybin C and isosilybin D due to their structural similarities to isosilybin A and isosilybin B, respectively, afforded a preliminary analysis of structure-activity relationships toward prostate cancer growth, survival, and apoptotic endpoints."
3.	Neoplasms (Cancer) 08/01/2013 - "In conclusion, silybin and isosilybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients. "